Jane Street’s Vor Biopharma VOR Stock Holding History

Jane Street’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,190	Closed	-$71K	–	11867
2025 Q2	$71K	Buy	+2,190	New	+$19.4K	﹤0.01%	9085

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Jane Street's VOR Position: Q2 2026 in Review

Jane Street sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 75,890 shares — an estimated $1.35M sold.

Jane Street first reported a position in VOR in Q3 2022 and held it in 13 quarters. The position peaked at $1.35M in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Jane Street reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
Jane Street sold 75,890 Vor Biopharma shares in Q2 2026, an estimated $1.35M.
Jane Street first reported a position in Vor Biopharma in Q3 2022 and held it in 13 quarters.
Jane Street's Vor Biopharma position peaked at $1.35M in Q1 2026.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.